Study Evaluating Etanercept 25mg or 50mg Administered Subcutaneously to Healthy Chinese Male Subjects
Phase 1
Completed
- Conditions
- Healthy
- Registration Number
- NCT00502879
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
The primary purpose of this study is to assess the pharmacokinetics of etanercept in healthy Chinese male subjects. Safety and tolerability data will also be obtained.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method To assess the pharmacokinetics of etanercept in healthy Chinese male subjects.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of etanercept in modulating TNF-alpha pathways in healthy subjects?
How does etanercept compare to other TNF inhibitors in pharmacokinetic profiles for Chinese populations?
What biomarkers correlate with etanercept's safety and tolerability in phase 1 trials?
What adverse events are associated with subcutaneous etanercept administration in healthy males?
How does etanercept's efficacy in rheumatoid arthritis relate to its pharmacokinetics in healthy individuals?